Centric Wealth Management Acquires 15,021 Shares of Johnson & Johnson $JNJ

Key Points

• Centric Wealth Management significantly increased its stake in Johnson & Johnson by 436.7%, acquiring an additional 15,021 shares, bringing their total holdings to 18,461 shares worth approximately $3.06 million.
• Johnson & Johnson recently declared a quarterly dividend of $1.30, with an annualized yield of 2.9%, payable on September 9th to stockholders of record.
• Analysts have mixed views on Johnson & Johnson, with ratings ranging from "strong buy" to "hold," while the average target price is set at $176.29.

Centric Wealth Management raised its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 436.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,461 shares of the company's stock after purchasing an additional 15,021 shares during the period. Centric Wealth Management's holdings in Johnson & Johnson were worth $3,062,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the company. Elios Financial Group Inc. grew its stake in Johnson & Johnson by 1.5% during the first quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock worth $746,000 after buying an additional 66 shares during the last quarter. Atlantic Family Wealth LLC lifted its stake in shares of Johnson & Johnson by 4.4% during the 1st quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock worth $266,000 after buying an additional 67 shares during the last quarter. MBA Advisors LLC raised its stake in Johnson & Johnson by 1.2% in the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock worth $921,000 after purchasing an additional 68 shares in the last quarter. Sovereign Financial Group Inc. boosted its holdings in shares of Johnson & Johnson by 1.8% in the 1st quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock valued at $651,000 after purchasing an additional 69 shares in the last quarter. Finally, Nabity Jensen Investment Management Inc lifted its position in shares of Johnson & Johnson by 1.5% in the 1st quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock worth $767,000 after purchasing an additional 69 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Stock Up 0.4%

NYSE JNJ traded up $0.64 during trading hours on Tuesday, reaching $177.81. 8,736,335 shares of the company's stock traded hands, compared to its average volume of 8,981,587. The firm has a 50-day simple moving average of $166.51 and a 200 day simple moving average of $160.21. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The firm has a market cap of $428.23 billion, a PE ratio of 19.02, a PEG ratio of 2.26 and a beta of 0.40. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Johnson & Johnson's quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the business earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's payout ratio is currently 55.61%.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Barclays increased their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. UBS Group raised their price objective on Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research report on Thursday, July 17th. Erste Group Bank raised Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Finally, Royal Bank Of Canada upped their target price on Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $176.29.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.